Clinical Trial Update: Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase I trial update of LCL161 in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic cancer. The status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Gemcitabine (Gemcitabine)
• LCL161

Snippet

Sponsor: US Oncology Research | Conditions: Metastatic Pancreatic Cancer | Phase 1 | Status: UNKNOWN